# Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

> **NCT00441155** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Nilotinib, Imatinib

## Key facts

- **NCT ID:** NCT00441155
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441155, "Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00441155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*